Compare AMBO & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMBO | SILO |
|---|---|---|
| Founded | 2000 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Apparel |
| Sector | Real Estate | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 6.4M |
| IPO Year | 2010 | 2011 |
| Metric | AMBO | SILO |
|---|---|---|
| Price | $2.46 | $0.44 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 78.7K | ★ 246.5K |
| Earning Date | 08-05-2025 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 337.04 | 57.98 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $9,469,000.00 | $72,102.00 |
| Revenue This Year | N/A | $1.86 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $331.08 | ★ N/A |
| Revenue Growth | ★ 0.82 | N/A |
| 52 Week Low | $1.47 | $0.22 |
| 52 Week High | $6.75 | $1.01 |
| Indicator | AMBO | SILO |
|---|---|---|
| Relative Strength Index (RSI) | 56.57 | 54.85 |
| Support Level | $2.55 | $0.33 |
| Resistance Level | $2.97 | $0.47 |
| Average True Range (ATR) | 0.35 | 0.04 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 73.03 | 90.56 |
Ambow Education Holding Ltd is an AI-driven technology educational company. Along with its subsidiaries, the company is developing a new HybriU AI Digital Education Solution that transforms the educational environment, bridging the gap between traditional methods and the future of digital learning. The solution combines sophisticated software and hardware to create an AI-powered digital and hybrid classroom, designed to enhance educational delivery and engagement. In addition, the group offers high-quality, individualized, and dynamic career education services and products through the operation of its for-profit colleges. Substantially the majority of the group's revenues are derived from the United States, based on the geographical locations where services are provided to customers.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.